Key Takeaways:
Multiple US law firms have filed class-action lawsuits against Immutep Limited (NASDAQ: IMMP), alleging the biotechnology company misled investors about the prospects of its lead cancer drug trial, which was abruptly halted for futility.
According to the lawsuits filed by firms including Bronstein, Gewirtz & Grossman, Rosen Law Firm, The Schall Law Firm, and Pomerantz LLP, Immutep made false and misleading statements regarding its TACTI-004 Phase III study of the drug eftilagimod alfa ("efti"). The complaints allege the company concealed that the trial was at high risk of failing to meet its primary endpoints.
The legal actions cover investors who purchased Immutep securities between March 24, 2025, and March 12, 2026. On March 13, 2026, Immutep announced that the trial's Independent Data Monitoring Committee recommended discontinuing the study. On this news, the price of Immutep's American Depositary Receipts (ADRs) collapsed, falling $2.27, or 82.44 percent, to close at $0.48 per ADR.
The lawsuits highlight a January 30, 2026, SEC filing where Immutep claimed the trial was showing "strong operational progress." The filings contend that at that time, the company was aware of information that materially increased the risk the study would fail. The deadline for investors to file a motion to serve as lead plaintiff in the case is July 6, 2026.
The legal challenges create significant uncertainty for Immutep, whose valuation was heavily tied to the success of eftilagimod alfa. For shareholders, the lawsuits offer a potential avenue to recover damages suffered from the stock's collapse, though the outcome is far from certain. The company's next catalyst will be its response to these allegations and any updates on its remaining clinical pipeline.
This article is for informational purposes only and does not constitute investment advice.
